Biomedical Engineering Reference
In-Depth Information
9. Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic
signaling. Cancer Treat. Res. 2003;115: 145-167.
10. Sawyers C. Targeted cancer therapy. Nature 2004;432(7015):294-297.
11. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety
of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N.
Engl. J. Med. 2001;344(14):1031-1037.
12. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic
breast cancer. Semin. Oncol. 2001;28 (6 Suppl. 18): 43-47.
13. Bauer KD, Jacobberger JW. Analysis of intracellular proteins. Methods Cell Biol. 1994;41:
351-376.
14. Chow S, Patel H, Hedley DW. Measurement of MAP kinase activation by flow cytometry
using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic
monitoring of signal transduction inhibitors. Cytometry 2001;46(2):72-78.
15. Perez OD, Nolan GP. Simultaneous measurement of multiple active kinase states using
polychromatic flow cytometry. Nat. Biotechnol. 2002;20(2):155-162.
16. ChowS, HedleyD, GromP, Magari R, Jacobberger JW, Shankey TV. Whole blood fixation
and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular
phosphorylated epitopes in leukocyte subpopulations. Cytometry A 2005;67(1):4-17.
17. Barnard D, Diaz B, Clawson D, Marshall M. Oncogenes, growth factors and phorbol esters
regulate Raf-1 through common mechanisms. Oncogene 1998;17(12):1539-1547.
18. Tong FK, Chow S, Hedley DW. Pharmacodynamic monitoring of BAY 43-9006
(Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients,
using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.
Cytometry B 2006;70: 107-114.
19. Green LJ, Marder P, Ray C, Cook CA, Jaken S, Musib LC, et al. Development and
validation of a drug activity biomarker that shows target inhibition in cancer patients
receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clin. Cancer Res. 2006;12
(11 Part 1): 3408-3415.
20. Rowlett RM, Chrestensen CA, Nyce M, Harp MG, Pelo JW, Cominelli F, et al. MNK
kinases regulate multiple TLR pathways and innate proinflammatory cytokines in
macrophages. Am. J. Physiol. Gastrointest. Liver Physiol. 2008;294(2):G452-G459.
21. Tudhope SJ, Finney-Hayward TK, Nicholson AG, Mayer RJ, Barnette MS, Barnes PJ, et
al. Different mitogen-activated protein kinase-dependent cytokine responses in cells of the
monocyte lineage. J. Pharmacol. Exp. Ther. 2008;324(1):306-312.
22. Bowers RK, Marder P, Green LJ, Horn CL, Faber AL, Thomas JE. A platelet biomarker for
assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy. Mol. Cancer
Ther. 2007;6(9):2600-2607.
23. Chow S, Minden MD, Hedley DW. Constitutive phosphorylation of the S6 ribosomal
protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients.
Exp. Hematol. 2006;34(9):1183-1191.
24. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT, et al. Single cell
profiling of potentiated phospho-protein networks in cancer cells. Cell 2004;118
(2):217-228.
25. Hamilton A, Elrick L, Myssina S, Copland M, Jorgensen H, Melo JV, et al. BCR-ABL
activity and its response to drugs can be determined in CD34
รพ
CML stem cells by CrkL
phosphorylation status using flow cytometry. Leukemia 2006;20(6):1035-1039.
Search WWH ::
Custom Search